Literature DB >> 3947807

The long-term hazards of the treatment of thyroid cancer with radioiodine.

C J Edmonds, T Smith.   

Abstract

Two-hundred and fifty-eight patients treated with high-activity 131I for thyroid cancer and on prolonged follow-up have been reviewed to determine long-term hazards and their relation to the radiation dose received. The expectation of life of those dying from causes other than cancer was slightly reduced in the female patients. A small, significant excess of deaths from cancer of the bladder and from leukaemia was found which, assuming that these were due to radiation, gave inferred risk-rates respectively of 0.4 and 4.9 deaths per 10(4) PYG (patient-year-grays) to the bladder wall and red marrow. Of 31 younger patients (eight male, 23 female), four of the marriages have been infertile. The fertile marriages produced a total of 44 live births. Considerable gonad irradiation (estimated 0.8-2.7 Gy) was compatible with apparently normal fertility. Despite the high level of irradiation of the salivary glands, no malignancies and only one adenoma was found. Impaired pulmonary function occurred in only one of the patients who had diffuse bilateral metastases. In this patient, tumour in the lung was persistent throughout, so that radiation was probably not alone responsible.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3947807     DOI: 10.1259/0007-1285-59-697-45

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  37 in total

Review 1.  Treatment of multinodular goiter by surgery.

Authors:  L J DeGroot
Journal:  J Endocrinol Invest       Date:  2001-11       Impact factor: 4.256

2.  Radionuclide therapy for thyroid disease.

Authors:  I R McDougall
Journal:  West J Med       Date:  1992-07

Review 3.  Papillary thyroid cancer: medical management and follow-up.

Authors:  Richard T Kloos
Journal:  Curr Treat Options Oncol       Date:  2005-07

4.  (131)I treatment for thyroid cancer and the risk of developing salivary and lacrimal gland dysfunction and a second primary malignancy: a nationwide population-based cohort study.

Authors:  Kuan-Yin Ko; Chia-Hung Kao; Cheng-Li Lin; Wen-Sheng Huang; Ruoh-Fang Yen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-04-22       Impact factor: 9.236

Review 5.  Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Gary L Francis; Steven G Waguespack; Andrew J Bauer; Peter Angelos; Salvatore Benvenga; Janete M Cerutti; Catherine A Dinauer; Jill Hamilton; Ian D Hay; Markus Luster; Marguerite T Parisi; Marianna Rachmiel; Geoffrey B Thompson; Shunichi Yamashita
Journal:  Thyroid       Date:  2015-07       Impact factor: 6.568

6.  Resveratrol mitigates genotoxicity induced by iodine-131 in primary human lymphocytes.

Authors:  Monireh Hedayati; Nayereh Shafaghati; Seyed Jalal Hosseinimehr
Journal:  Radiat Environ Biophys       Date:  2013-02-23       Impact factor: 1.925

7.  Functioning pulmonary metastases of thyroid cancer: does radioiodine influence the prognosis?

Authors:  Elif Hindié; Didier Mellière; Françoise Lange; Iyad Hallaj; Claire de Labriolle-Vaylet; Christian Jeanguillaume; Jacques Lange; Léon Perlemuter; Serge Askienazy
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-05-07       Impact factor: 9.236

Review 8.  Thyroid cancer: a review of treatment and follow-up.

Authors:  L Vini; C Harmer; V R McCready
Journal:  Ann Nucl Med       Date:  1996-02       Impact factor: 2.668

Review 9.  Thyroid disease and male reproductive function.

Authors:  G E Krassas; P Perros
Journal:  J Endocrinol Invest       Date:  2003-04       Impact factor: 4.256

10.  Feasibility of radioimmunotherapy of experimental pneumococcal infection.

Authors:  E Dadachova; T Burns; R A Bryan; C Apostolidis; M W Brechbiel; J D Nosanchuk; A Casadevall; L Pirofski
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.